Abstract
Introduction
Lung cancer is the most common malignancy and cause of cancer-related deaths worldwide, particularly non-small cell lung cancer (NSCLC). This may be due to approximately 57% of all lung cancers being found at an advanced stage at diagnosis [1, 2] . The accepted standard dual regimen chemotherapy consisting of paclitaxel and a platinum agent demonstrates consistent objective re-sponses [3] . However, the 5-year survival rate is still low [4] and treatment efficacy needs to be improved.
Solid tumour growth requires both nutrients and oxygen, which is facilitated by vessel angiogenesis to enable energetic tumour cell proliferation [5] . Therefore, antiangiogenesis has represented a new approach for targeted cancer therapy [6] . Recent clinical studies have demonstrated patients with advanced SCLCs benefitting further from anti-angiogenic therapy, when combined with chemotherapeutic regimes [7, 8] .
Endostatin is an endogenous angiogenic inhibitor with strong anti-angiogenic activity that can inhibit the growth of various tumours and prevent the progression of metastasis [9] . Endostar, a novel recombinant human endostatin with an additional 9-amino acid sequence (MGGSHHHHH) at the N terminus, increased heat stability and proteolytic resistance compared to endogenous endostatin [10] . It has been reported that Endostar, as an angiogenic inhibitor, strongly inhibits the growth of a variety of murine and xenotransplanted human tumours [11] . The clinical studies show that Endostar combined with first-line chemotherapy (vinorelbine-cisplatin or paclitaxel-carboplatin) in patients with advanced NSCLC significantly improved the progression-free survival (PFS) and overall survival (OS) time [12] .
Endostar is recommended to be administered by intravenous infusion once per day for 4 h; nevertheless, its half-life in vivo is only 10 h, and thus the efficacy of Endostar is limited. The mini-osmotic pump is a modality for delivering a continuous infusion, which is able to deliver a variety of solutions or suspensions at a constant rate for days and even up to several weeks, thereby enabling an effective concentration of drug to be maintained and the efficacy of the drug enhanced. Here, we investigated whether durative transfusion of Endostar combined with chemotherapy could enhance the efficacy in advanced NSCLC compared to intravenous infusion once a day combined with chemotherapy for 10 days.
Materials and Methods

Eligibility/Inclusion Criteria
Retrospective data of all consecutive patients with pathologically confirmed stage IIIB-IV NSCLC were collected and analysed over a 5-year period. These patients were staged according to the American Joint Committee on Cancer Staging System. All patients were required to have at least one measurable tumour, which was not amenable to surgical excision. Further eligibility criteria required patients to be older than 18 years of age, have Karnofsky performance status > 70 points, and have life expectancy > 3 months. Finally, all patients' blood routine, liver and kidney function, and electrocardiogram were identified as normal before the trial.
Patients were split into two groups where those undergoing standard intravenous chemotherapy were defined as the control group and those undergoing treatment with durative pump chemotherapy were defined as the treatment group. Due to the nature of a retrospective review of approved treatment regimens, which does not include experimental trials, submission to and approval of a formal ethics committee was not required.
Therapy Schedule
The control group received intravenous infusion of Endostar once per day combined with chemotherapy, whilst the test group was treated with durative transfusion of Endostar for 10 days in each chemotherapy cycle. The chemotherapeutics for both groups were mainly docetaxel, gemcitabine, pemetrexed, cisplatin, and nedaplatin. For the intravenous infusion, Endostar was given daily at a dose of 15 mg in 500 mL of saline for 4 h from day 1 to day 14 and repeated 7 days later. For the durative transfusion, Endostar was continuously pumped at the rate of 5 mL/h (210 mg in 279 mL of saline) by the mini-osmotic pump (DBB-I-I type; Love's Scientific Instrument Co., Ltd., China) from day 1 to day 10. During the administration of Endostar, patient heart rate, blood pressure, pulse oxygen saturation, and electrocardiogram were continuously monitored using an IntelliVue MP20 patient monitor (Royal Philips Electronics, the Netherlands).
Evaluation of Efficacy
The clinical symptoms and signs, side effects, and blood routine were examined every week. Blood chemistry and electrocardiogram were performed in every cycle. Efficacy was evaluated by CT scan in each cycle according to the Response Evaluation Criteria in Solid Tumours (RECIST) including complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). The disease control rate (DCR) was defined as the percentage of patients with CR, PR, or SD. The overall response rate (ORR) was defined as the percentage of patients with CR or PR. OS was defined as the time from first treatment to death while PFS was considered as the time from randomization to tumour progression or death from any cause.
Statistical Analysis
Statistical analysis was performed using SPSS 18.0 statistical package. The short-term efficacy between the two groups was analysed by χ 2 test. The differences in Karnofsky performance status were analysed by t test. Survival curves were drawn by the KaplanMeier method using GraphPad prism software. A log-rank test was used to compare the survival rates of the two groups. A value of p < 0.05 was considered to be statistically significant.
Results
Patient Characteristics
A total of 116 patients were enrolled in the study, with an even split of 58 patients in both the control and treatment group. Characteristics of the patients are summarized in Table 1 . The control group comprised 37 males DOI: 10.1159/000493098 and 21 females (age range 45-70 years), whereas the treatment group consisted of 40 male and 18 female patients (age range 41-67 years). There was no statistically significant difference in age, gender, clinical stage, smoking status, Karnofsky performance status, epidermal growth factor receptor (EGFR) status, and histology between the two groups.
Response to Therapy
Following treatment, we observed that the control group had 1 case of CR, 13 cases of PR, and 16 cases of SD. The test group had 0 cases of CR, 22 cases of PR, and 14 cases of SD. The ORR (CR + PR) between the two groups was similar. However, the DCR of the test group was significantly improved, when compared to the control group (p < 0.01) ( Table 2) . Importantly, the median PFS was significantly improved from 4 months in the control group to 6 months in the test group (p = 0.037) (Fig. 1a) . The median OS time was also seen to be extended from 13.5 months in the control group to 17.5 months in the test group (p = 0.034) (Fig. 1b) . Finally, the 1-year survival rate of the test group and the control group was seen to be 9.7 and 15.8%, respectively.
Safety
Patients were carefully monitored for significant, unintended and unwanted side effects. Mild to moderate side effects such as fatigue, vomiting, diarrhoea, and myelosuppression were tolerated well by all patients (Table  3 ). There were no significant differences in side effects between the two groups. Only 1 case in the test group had grade IV myelosuppression and recovered after injection of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-11. There were no treatment-related deaths.
Discussion
In the treatment of NSCLC, the efficacy of first-line platinum-containing regimen of dual regimen therapy has reached a bottleneck. The addition of anti-angiogenic drugs can improve efficacy and prolong survival. These have been confirmed previously by ECOG 4599 and BE-YOND clinical trials. Endostar is a vascular endothelial inhibitor, which was developed in China independently, and its mechanism is different from bevacizumab (anti-VEGF receptor monoclonal antibody).
Phase IV clinical trials showed that applying Endostar both in first-line and second-line chemotherapy in the treatment of NSCLC could increase ORR and 1-year survival rate [13] . Therefore, this study changes the mode of Control group: intravenous infusion; test group, durative transfusion; M(+), mutation-positive; M(-), mutation-negative; NE, not evaluated. administration, using a continuous infusion method, to maintain a stable blood concentration. Compared to traditional intravenous infusion for 4 h per day, the continuous infusion mode is safer and can improve patients' compliance, shorten the time in hospital, and cut costs. Previously, a number of studies have demonstrated that Endostar can maintain the stability of physical and chemical properties under normal conditions at high concentration in vitro.
Endostatin, an endogenous angiogenic inhibitor, has been shown to inhibit VEGF, metalloproteinases, integrins, c-myc, cyclin D1, and even the Wnt signalling pathway [14] . In vitro, Endostar (a recombinant human endostatin) can inhibit the growth of human lung adenocarcinoma cell line SPC-A4, the migration of human umbilical vein endothelial cell (HUVEC), and angiogenesis of the chorioallantoic membrane [15] . Furthermore, Endostar can suppress tumour growth in mouse models (S180 sarcoma, H22 liver cancer) and human xenograft models (SPC-A4 lung adenocarcinoma, SGC7901 gastric cancer, HeLa cervical cancer, SMMC-7721 and Bel7402 liver cancer). It has been reported that Endostar can suppress not only angiogenesis but also lymph node metastasis [16, 17] . The addition of Endostar results in significant improvement in response rate, median time to tumour progression, and clinical benefit rate in patients with advanced NSCLC [12, [18] [19] [20] . Since 2007, Endostar There was no significant difference in the side effects between the two groups demonstrated. There were no treatment-related deaths. could be used as a first-line agent together with chemotherapy in the treatment of NSCLC [21] . No death related to Endostar has been reported. In phase I-III clinical studies, heart reaction was the main adverse event in dose-limited toxicity of Endostar and arrhythmia was the most common case [22, 23] .
Our results showed that durative transfusion of Endostar significantly improved the DCR and PFS compared to intravenous infusion, although there was no significant difference in the ORR between the two groups. Importantly, the OS in the test group was significantly extended compared to the control group. In the literature, a randomized, double-blind, placebo-controlled study demonstrated that Endostar plus chemotherapy caused only grade 1 and grade 2 cardiac ischemia in patients, but no significant difference was noted in OS and PFS between the treatment and control groups [24] . The different timing, sequence, or dose of the anti-angiogenic drugs in combination with cytotoxic chemotherapy drugs might have resulted in the distinct clinical efficacy, but we thought that the different injection methods might be the major reason. The mini-osmotic pump was used for the durative transfusion of Endostar in our study, which can maintain a stable and effective blood drug concentration. Therefore, the efficacy of Endostar was improved. Furthermore, manageable side effects were observed in our study and there was no significant difference in the two groups. Previously, in a determination of Endostar concentration test, to exclude the effects of residual drug released from the osmotic pump 24 h after termination of pump flow, the concentrations of Endostar in serum of the control and test groups were tested at that time point. Only nanogram amounts of drug were detected in the serum of the two groups and there was no difference, indicating that the difference between the two groups was not due to the residual Endostar in the pump [25] .
In conclusion, the continuous administration of Endostar combined with chemotherapy for advanced NSCLC results in a higher DCR and longer PFS, with tolerable adverse effects. Further work would include prospective randomization studies to further evaluate treatment response.
